[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100135632":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":32,"centralContacts":11,"locations":36,"responsibleParty":63,"collaborators":11,"id":65,"slug":66,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":11,"eligibilityCriteria":71,"healthyVolunteers":72,"sex":73,"minAge":74,"maxAge":11,"enrollmentInfo":75,"targetDuration":11,"studyType":78,"phases":79,"briefSummary":81,"conditions":82,"keywords":85,"overallStatus":90,"whyStopped":11,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},{"fullName":5,"class":6},"Bayer","INDUSTRY",[8,14,17],{"label":9,"type":10,"description":11,"interventionNames":12},"Arm 1","EXPERIMENTAL",null,[13],"Drug: F-18 FEDAA1106 (BAY85-8101)",{"label":15,"type":10,"description":11,"interventionNames":16},"Arm 2",[13],{"label":18,"type":10,"description":11,"interventionNames":19},"Arm 3",[13],[21,26,29],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":11},"DRUG","F-18 FEDAA1106 (BAY85-8101)","Alzheimer Disease patients: Single intravenous bolus injection of 250 MBq BAY85-8101 on day one of the treatment period, PET",[9],{"type":22,"name":23,"description":27,"armGroupLabels":28,"otherNames":11},"Healthy volunteers for brain imaging: Single intravenous bolus injection of 250 MBq BAY85-8101 on day one of the treatment period, PET",[15],{"type":22,"name":23,"description":30,"armGroupLabels":31,"otherNames":11},"Healthy volunteers for whole body imaging: Single intravenous bolus injection of 185 MBq BAY85-8101, whole body PET for evaluation of effective dose, kinetics of BAY85-8101 in blood",[18],[33],{"name":34,"affiliation":5,"role":35},"Bayer Study Director","STUDY_DIRECTOR",[37,48,58],{"facility":11,"status":11,"city":38,"state":11,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":11},"Amsterdam","1081 HV","Netherlands","NL",{"type":43,"coordinates":44},"Point",[45,46],4.88969,52.37403,{"lat":46,"lon":45},{"facility":11,"status":11,"city":49,"state":11,"zip":50,"country":51,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":57,"contacts":11},"Stockholm","141 86","Sweden","SE",{"type":43,"coordinates":54},[55,56],18.06871,59.32938,{"lat":56,"lon":55},{"facility":11,"status":11,"city":49,"state":11,"zip":59,"country":51,"countryCode":52,"cosmosGeoPoint":60,"geoPoint":62,"contacts":11},"171 76",{"type":43,"coordinates":61},[55,56],{"lat":56,"lon":55},{"type":64,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100135632","phase-1-evaluation-of-zk-6032924-in-probable-alzheimers-disease-patients-versus-healthy-volunteers-and-the-radiation-dosimetry-of-zk-6032924-in-healthy-volunteers-100135632",false,"NCT01035164","Evaluation of ZK 6032924 in Probable Alzheimer's Disease Patients Versus Healthy Volunteers and the Radiation Dosimetry of ZK 6032924 in Healthy Volunteers","Open-label, Non-randomized, Positron Emission Tomography (PET) Imaging Study to Evaluate a Single Dose of 250 MBq (6.75 mCi) ZK 6032924 (18F-FEDAA1106) for Its Diagnostic Potential in Discriminating Patients With Probable Alzheimer's Disease From Healthy Volunteers and to Evaluate the Radiation Dosimetry of a Single Dose of 185 MBq (5 mCi) ZK 6032924 in Healthy Volunteers.","Inclusion Criteria:Patients for brain imaging:- patient and designee capable of giving fully informed consent in writing- patient fulfils DSM-IV and NINCDS-ADRDA criteria for probable Alzheimer's disease. Other forms of dementia excluded- males or postmenopausal females aged \\>\u002F= 50 yearsHealthy volunteers for brain imaging: - able to give fully informed consent in writing- absence of any sign of dementia\u002Fcognitive impairment in neuropsychological examinations- males or postmenopausal females aged \\>\u002F= 50 years Healthy volunteers for whole body imaging:- able to give fully informed consent in writing - males or postmenopausal females aged \\>\u002F= 60 years - no significant disease or drug use Exclusion Criteria:For all healthy volunteers and patients:- Any disease, condition, or concomitant medications that significantly compromises the function of the body systems and could result in excessive accumulation, impaired metabolism, altered excretion of the radiotracer, or might interfere with the conduct of the study or interpretation of the results",true,"ALL","50 Years",{"count":76,"type":77},25,"ACTUAL","INTERVENTIONAL",[80],"PHASE1","PET (positron emission tomography) imaging with BAY85-8101 (ZK 6032924) in patients with Alzheimer's Disease compared to healthy volunteers.",[83,84],"Positron-Emission Tomography","Alzheimer's Disease",[84,86,87,88,89],"Diagnostic Imaging","Neuroinflammation","PET Diagnosis","PET Tracer","COMPLETED","2015-01-07",{"date":93,"type":94},"2015-01-08","ESTIMATED",{"date":96,"type":11},"2007-06",{"date":98,"type":77},"2010-01",{"name":5,"class":6},3]